AEON Biopharma (AEON) Total Non-Current Liabilities (2020 - 2026)

AEON Biopharma has reported Total Non-Current Liabilities for 6 years, with the latest figure at $45.7 million in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 49.74% year-over-year to $45.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $45.7 million (up 49.74% YoY) and the FY2025 annual result came in at $45.7 million, up 49.74% from the prior year.
• Total Non-Current Liabilities improved to $45.7 million in Q4 2025 per AEON's latest filing, from $26.3 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $143.8 million in Q3 2023 and troughed at $7.6 million in Q1 2023.
• A 5-year average of $28.2 million and a median of $21.1 million in 2021 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities jumped 17511.91% in 2021, then plunged 79.69% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $10.5 million in 2021, then advanced by 13.87% to $12.0 million in 2022, then jumped by 364.76% to $55.5 million in 2023, then slumped by 45.04% to $30.5 million in 2024, then jumped by 49.74% to $45.7 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $45.7 million, $26.3 million, and $25.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.